Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
LLKKLLKK details |
| Primary information | |
|---|---|
| ID | antitb_1230, |
| Name | 24314557 |
| N-Terminal modification | (LLKK)2 |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis (ATCC No. 14468) |
| Cell Line | MIC = 125 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1231, |
| Name | 24314557 |
| N-Terminal modification | (LLKK)2 |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG lux |
| Cell Line | MIC = 500 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1232, |
| Name | 24314557 |
| N-Terminal modification | (LLKK)2 |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC > 500 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1233, |
| Name | 24314557 |
| N-Terminal modification | (LLKK)2 |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis CSU87 reistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin |
| Cell Line | MIC > 500 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1616, |
| Name | 26380930 |
| N-Terminal modification | LK |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC14468 |
| Cell Line | MIC = 125 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= >500 μg/ml |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1622, |
| Name | 26380930 |
| N-Terminal modification | LK |
| C-Terminal Modification | LLKKLLKK |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 8 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC14468 |
| Cell Line | MIC = 62.5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= >500 μg/ml |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | Peptide + Rifampicin (0.98 μg/ml) |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |